ARK Investment Management LLC Boosts Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

ARK Investment Management LLC lifted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 16.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 32,769,186 shares of the company's stock after purchasing an additional 4,626,268 shares during the quarter. Recursion Pharmaceuticals comprises about 2.0% of ARK Investment Management LLC's investment portfolio, making the stock its 16th biggest position. ARK Investment Management LLC owned about 11.66% of Recursion Pharmaceuticals worth $215,949,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC bought a new stake in shares of Recursion Pharmaceuticals in the third quarter worth about $25,000. Farther Finance Advisors LLC grew its position in Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock worth $42,000 after acquiring an additional 4,091 shares in the last quarter. GAMMA Investing LLC grew its position in Recursion Pharmaceuticals by 1,588.4% in the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company's stock worth $48,000 after acquiring an additional 6,036 shares in the last quarter. Amalgamated Bank grew its position in Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company's stock worth $54,000 after acquiring an additional 2,459 shares in the last quarter. Finally, San Luis Wealth Advisors LLC purchased a new position in Recursion Pharmaceuticals in the third quarter worth about $69,000. 89.06% of the stock is owned by institutional investors.

Insider Transactions at Recursion Pharmaceuticals

In other news, CFO Michael Secora sold 15,000 shares of the company's stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $6.35, for a total transaction of $95,250.00. Following the transaction, the chief financial officer now directly owns 1,340,968 shares of the company's stock, valued at approximately $8,515,146.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CFO Michael Secora sold 15,000 shares of the business's stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $6.35, for a total transaction of $95,250.00. Following the sale, the chief financial officer now directly owns 1,340,968 shares of the company's stock, valued at $8,515,146.80. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Tina Marriott sold 6,000 shares of the business's stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $7.56, for a total transaction of $45,360.00. Following the sale, the chief operating officer now directly owns 521,138 shares in the company, valued at $3,939,803.28. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 171,682 shares of company stock valued at $1,107,868. Corporate insiders own 15.75% of the company's stock.

Recursion Pharmaceuticals Price Performance

NASDAQ:RXRX traded up $0.17 during trading hours on Friday, reaching $7.10. The company's stock had a trading volume of 6,659,177 shares, compared to its average volume of 5,672,606. Recursion Pharmaceuticals, Inc. has a 12 month low of $5.03 and a 12 month high of $15.74. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.07 and a current ratio of 6.07. The stock has a 50 day moving average price of $6.58 and a two-hundred day moving average price of $7.63.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.01). The business had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 78.21% and a negative net margin of 579.52%. The business's quarterly revenue was up 147.6% on a year-over-year basis. During the same period last year, the firm earned ($0.43) EPS. Analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on RXRX shares. Leerink Partners dropped their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating for the company in a research report on Tuesday, September 3rd. Jefferies Financial Group dropped their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating for the company in a research report on Tuesday, September 3rd. Needham & Company LLC restated a "buy" rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday. Finally, KeyCorp dropped their target price on Recursion Pharmaceuticals from $16.00 to $12.00 and set an "overweight" rating for the company in a research report on Thursday, July 11th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $9.40.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.